
Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

Corporate venture arm of Merck investing globally in healthcare, life sciences, electronics and sustainability

Merck KGaA of Darmstadt, Germany runs M Ventures as its strategic corporate venture fund. The fund invests in biotechnology and technology companies with both strategic and financial aims, and it takes an active role in its portfolio, teaming up with management teams and co-investors to turn scientific discoveries into commercial success.
The biotechnology team invests in emerging companies developing differentiated medicines, platforms and technologies, and it also creates spin-out companies from Merck. In life sciences it backs companies building tools, technologies and services that make research and biotech manufacturing faster and more efficient. Examples named by the fund include Trimtech Therapeutics, which develops small-molecule degraders of toxic protein clumps for neurodegenerative disease, and LabGenius, which works on antibody discovery.
The technology team covers electronics, frontier technology and sustainability, with interests in computing, data storage, displays and device miniaturisation. Portfolio examples include Tignis, which applies physics and machine learning to process control in semiconductor manufacturing, MemryX, a fabless chip company that designs edge AI processors, and Future Fertility, which develops AI-enabled, non-invasive fertility diagnostics.
The biotechnology team also runs the M Ventures Israel Bioincubator, which helps academic research mature into independent, well financed companies. The incubator focuses on company creation and early-stage investment, and is home to several portfolio companies.
Since its start in 2009, the firm reports creating or growing more than 80 companies, and it reports more than 100 investments in total. Its four focus areas are healthcare, life sciences, electronics and frontier technology, and sustainability, chosen to match the interests of Merck's business areas. The fund has its headquarters in the Netherlands and offices in Germany, the USA and Israel.
M Ventures is the strategic venture capital arm of Merck. It invests in entrepreneurs with fresh ideas, aiming for both strategic and financial returns, and says it has helped create and grow more than eighty companies.
Entrepreneurs and management teams, and co-investors who join its deals. Its four focus areas match the interests of Merck's business areas.
Summary written by TrustList from the business's own published information, Nov 2026.
1 image - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about M Ventures.
Similar listings buyers compare against this one.

Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

Global venture capital partnership investing in data, technology and analytics companies, backed by RELX Group

Investment management firm focused on the global financial services industry and its owner-operators

Venture investor giving family offices and wealthy individuals access to UK technology companies

Israeli venture capital fund backing pre-seed and seed technology founders

Software-focused investor backing small technology companies in the north-eastern United States and nearby states

A venture capital firm in the SF Bay Area investing since 1995

Venture capital firm investing in climate tech, biotech, aerospace and next-generation computing companies
Everything here links back to the same verified catalogue. Pick your next stop.